Xilio Therapeutics (XLO) Liabilities and Shareholders Equity (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $163.5 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 57.63% year-over-year to $163.5 million; the trailing twelve-month figure through Mar 2026 stood at $585.7 million (up 72.6% YoY), and the FY2025 full-year result was $154.7 million, up 117.64% from the prior year.
• Liabilities and Shareholders Equity climbed to $163.5 million in Q1 2026, from $154.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $196.4 million in Q1 2022 to a low of $60.9 million in Q4 2023.
• A 5-year average of $118.9 million and a median of $111.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 56.22% in 2023 and surged 117.64% in 2025, its largest moves.
• Tracing XLO's Liabilities and Shareholders Equity over 5 years: stood at $139.2 million in 2022, then plunged by 56.22% to $60.9 million in 2023, then grew by 16.66% to $71.1 million in 2024, then surged by 117.64% to $154.7 million in 2025, then increased by 5.69% to $163.5 million in 2026.
• Business Quant data shows XLO's Liabilities and Shareholders Equity at $163.5 million in Q1 2026, $154.7 million in Q4 2025, and $133.7 million in Q3 2025.